Puma Biotechnology Inc. (PBYI)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
PBYI Chart
People also search for
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 406 | $2,305.77 | $3,243.94 | $938.17 | 40.69% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 500 | $3,195 | $4,385 | $1,190 | 37.25% |
| NA Nizar Araji National Bank Of Canada /FI/ | 19 | $154.09 | $169.29 | $15.2 | 9.86% |
| BG Bart Gancher Intech Investment Management LLC | 10,210 | $82,803.1 | $90,971.1 | $8,168 | 9.86% |
 Joseph Castro Nuveen LLC | 82,298 | $260,066.68 | $715,169.62 | $455,102.94 | 174.99% |
Puma Biotechnology Inc. (PBYI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Puma Biotechnology Inc. ever had a stock split?
Puma Biotechnology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alan H. Auerbach CEO | NASDAQ (NGS) Exchange | 74587V107 CUSIP |
| US Country | 179 Employees | - Last Dividend | - Last Split | 24 Apr 2012 IPO Date |
Overview
Puma Biotechnology, Inc. is a biopharmaceutical company with a sharp focus on the development and commercialization of innovative products aimed at improving cancer care, both within the United States and globally. Since its establishment in 2010, the company has been dedicated to bringing forward novel therapies that cater to specific cancer care needs. With headquarters in Los Angeles, California, Puma Biotechnology has built a strong presence in the oncology space through its strategic license agreements for the development, manufacture, and commercialization of key compounds with leading pharmaceutical companies such as Pfizer Inc. and Takeda Pharmaceutical Company Limited. Moreover, the company extends its market reach through sub-license agreements with several international pharmaceutical companies, facilitating the global distribution of its oncology products.
Products and Services
-
NERLYNX (neratinib, oral)
This is an oral medication developed by Puma Biotechnology, designed specifically for the treatment of adult patients who are dealing with early-stage HER2-overexpressed/amplified breast cancer. In addition, NERLYNX, when combined with capecitabine, is indicated for patients suffering from advanced or metastatic HER2-positive breast cancer. This highlights the company's dedication to providing targeted therapies for patients with specific cancer types, offering them a chance for a better quality of life and improved treatment outcomes.
-
Alisertib (small molecule inhibitor of aurora kinase A)
Currently under development, alisertib represents Puma Biotechnology's commitment to expanding its oncology portfolio. This small molecule inhibitor targets aurora kinase A, a protein associated with cellular division and is implicated in various types of cancer. Puma Biotechnology is exploring alisertib's potential in treating hormone receptor-positive breast cancer, triple-negative breast cancer, small cell lung cancer, and head and neck cancer. This signifies the company's investment in broadening the scope of its research and development efforts to encompass a wider array of cancer types, aiming to fill therapy gaps and meet the diverse needs of cancer patients.
